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Summary
 
Xenotransplantation could overcome the severe shortage of allogeneic organs, a major factor
limiting organ transplantation. Unfortunately, transplantation of organs from pigs, the most
suitable potential donor species, results in hyperacute rejection in primate recipients, due to the
presence of anti–Gal
 
a
 
1-3Gal (Gal) natural antibodies (NAbs) in their sera. We evaluated the
ability to tolerize anti-Gal NAb–producing B cells in 
 
a
 
1,3-galactosyltransferase knockout
(GalT KO) mice using bone marrow transplantation (BMT) from GalT
 
1
 
/
 
1
 
 wild-type (WT)
mice. Lasting mixed chimerism was achieved in KO mice by cotransplantation of GalT KO
and WT marrow after lethal irradiation. The levels of anti-Gal NAb in sera of mixed chimeras
were reduced markedly 2 wk after BMT, and became undetectable at later time points. Immu-
nization with Gal
 
1
 
/
 
1
 
 xenogeneic cells failed to stimulate anti-Gal antibody production in
mixed chimeras, whereas the production of non–Gal-specific antixenoantigen antibodies was
stimulated. An absence of anti-Gal–producing B cells was demonstrated by enzyme-linked im-
munospot assays in mixed KO
 
1
 
WT
 
®
 
KO chimeras. Thus, mixed chimerism efficiently in-
duces anti-Gal–specific B cell tolerance in addition to T cell tolerance, providing a single
approach to overcoming both the humoral and the cellular immune barriers to discordant xe-
notransplantation.
 
A
 
lthough modern immunosuppressive therapies have
improved the success of clinical organ transplantation,
a severe shortage of allogeneic organs currently limits the
number of transplants performed (1, 2). Given the urgent
need for donor organs and the problems associated with the
use of nonhuman primates, interest has become focused on
the potential use of nonprimates as organ donors for hu-
mans. The species generally believed to be most suitable for
this purpose is the pig (2–4). However, xenotransplantation
from evolutionarily distant species such as the pig poses for-
midable obstacles. One particularly imposing challenge arises
from the presence of preexisting, or “natural,” xenoreac-
tive antibodies (NAbs)
 
1
 
 at high titers in the sera of all hu-
mans (5). These NAbs are major effectors of hyperacute re-
jection. Furthermore, even if NAbs are absorbed or in
some way removed before xenogeneic organ transplanta-
tion, their return is associated with the phenomenon of de-
layed xenograft rejection/acute vascular rejection (2, 6–8).
Most of the NAb activity against porcine cells in human
sera is directed against the Gal
 
a
 
1-3Gal
 
b
 
1-4GlcNAc-R
epitope, which is widely expressed on glycoproteins and
glycolipids of most mammalian species, including swine (9–
11). Although a number of strategies have been used to
promote successful xenotransplantation by targeting differ-
ent steps in the progression of NAb-mediated rejection,
none has proved entirely successful. The elimination of
anti-Gal NAb from recipients by immunoabsorption by
donor-species organ hemoperfusion (12) or immunoaffin-
ity columns of synthetic oligosaccharides (13, 14), or by
treatment with anti-Ig antibodies (15) has been found ef-
fective in preventing or delaying hyperacute rejection (13–
15). However, the efficiency of such treatments is short-
lived, as NAb levels return rapidly to their original levels
and participate in the delayed rejection of xenografts. In
view of the ability of NAb to initiate complement-inde-
pendent changes in endothelium, to participate in anti-
body-dependent cell-mediated cytotoxicity against porcine
 
1
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a
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a
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cells, and to play a role in delayed xenograft rejection/acute
vascular rejection, inactivation of the recipient complement
system (2, 8, 10) or approaches to reducing Gal epitope
density (16–18) alone would be unlikely to permit long-
term xenoengraftment.
Previous studies have demonstrated that induction of a
state of mixed hematopoietic chimerism can lead to perma-
nent tolerance of T cells to allogeneic and concordant xenoge-
neic antigens, with excellent immunocompetence (19–23).
In addition, reductions in mouse IgM NAbs capable of
binding to rat bone marrow cells (BMC) were observed in
rat
 
®
 
mouse mixed chimeras (24), suggesting that NAb-
forming B cells might also be tolerized by this approach.
Recently, mice homozygous for a null 
 
a
 
1,3-galactosyl-
transferase allele (GalT KO) have been generated by tar-
geted disruption of the murine 
 
a
 
1,3GalT gene (25). As in
humans, sera of these animals contain anti-Gal NAb, thus
providing a model in which to evaluate methods of induc-
ing anti-Gal NAb tolerance. We have now evaluated the
possibility of achieving mixed chimerism in GalT KO mice
by transfer of GalT
 
1
 
/
 
1
 
 wild-type (WT) mouse BMC with
GalT KO mouse marrow to lethally irradiated GalT KO
mouse recipients, in order to determine the potential of mixed
chimerism to tolerize anti-Gal NAb–producing B cells.
 
Materials and Methods
 
Animals.
 
GalT KO (Gal
 
2
 
/
 
2
 
, H-2
 
d
 
) and GalT
 
1
 
/
 
1
 
 WT (H-
2
 
bxd
 
) mice were derived from hybrid (129SV 
 
3
 
 DBA/2 
 
3
 
C57BL/6) animals (25). C.B-17 
 
scid
 
/
 
scid
 
 (C.B-17 
 
scid
 
) and re-
combination activating gene 1 (RAG-1)–deficient (mixed B6 and
129 background) mice were purchased from the Department of
Radiation Oncology of Massachusetts General Hospital (Boston,
MA), and The Jackson Laboratory (Bar Harbor, ME), respec-
tively. Mice were housed in sterilized microisolator cages and re-
ceived autoclaved feed and autoclaved, acidified drinking water.
 
Bone Marrow Transplantation.
 
BMC were T cell–depleted (TCD)
using anti-CD4 and anti-CD8 mAbs and rabbit complement as
described (26, 27). Recipients were treated with 9.75 Gy whole
body irradiation from a 
 
137
 
Cs source (0.97 Gy/min), followed within
4–6 h by i.v. infusion of TCD BMC.
 
Flow Cytometric Analysis of Chimerism.
 
Single-cell suspensions
were incubated with anti–WT mouse H-2K
 
b
 
 5F1-FITC and PE-
labeled anti-CD19 (for B cell chimerism), or anti–CD4-PE plus
anti–CD8-PE (for T cell chimerism) (for two-color flow cyto-
metric [FCM] analysis), or with 5F1-FITC, anti–CD19-PE, and
anti–CD4-Bio plus anti–CD8-Bio (for three-color FCM analysis)
mAbs (PharMingen, San Diego, CA) as described (27). Nonspe-
cific Fc
 
g
 
R binding was blocked with rat anti–mouse Fc
 
g
 
R mAb
2.4G2 (28) as described (27). FITC-labeled and biotinylated
mouse IgG2a mAb HOPC-1 and PE-labeled rat IgG2a mAb
(PharMingen) were used as nonstaining negative control antibod-
ies. FCM analysis was performed on a FACScan
 
Ò
 
 cytometer
(Becton Dickinson, Mountain View, CA).
 
ELISA for Detecting Mouse NAb Reactive with Gal.
 
96-well mi-
crotiter ELISA plates (Corning Glass Works, Corning, NY) were
coated overnight at 4
 
8
 
C with 100 
 
m
 
l of 5 
 
m
 
g/ml of 
 
a
 
Gal(1
 
®
 
3)
 
b
 
Gal
(1
 
®
 
4) conjugated to BSA (Alberta Research Council, Alberta,
Canada) in bicarbonate buffer (0.05 M NaHCO
 
3
 
, pH 9.6). The
wells were washed five times with PBS/Tween-20 (0.05%
Tween-20). Plates were blocked with 200 
 
m
 
l/well of 1% BSA in
PBS/Tween-20 for 1 h at 37
 
8
 
C and washed five times. Serum
samples were serially diluted in PBS/Tween-20, and triplicate
samples of 100 
 
m
 
l/well were added to wells. Plates were incu-
bated for 1 h at 37
 
8
 
C, then washed five times with PBS/Tween-
20. Bound antibodies were detected using 100 
 
m
 
l/well of horse-
radish peroxidase–conjugated polyclonal donkey anti–mouse IgM
and IgG antibodies (Accurate Chemical and Scientific Corp.,
Westbury, NY) at 250 ng/ml. Plates were incubated for 1 h at
37
 
8
 
C, and washed five times with PBS/Tween-20. Color devel-
opment was achieved using 100 
 
m
 
l of 0.01 mg/ml 
 
o
 
-phenylenedi-
amine dihydrochloride (OPD; Sigma Chemical Co., St. Louis,
MO) in substrate buffer (0.1 M sodium citrate, 0.012% H
 
2
 
O
 
2
 
, pH
4.5). After 30 min of incubation at room temperature and in
complete darkness, the OPD reaction was stopped using 50 
 
m
 
l of
3 M NH
 
2
 
SO
 
4
 
, and absorbance at 492 nm was measured using an
ELISA reader (SLT Labinstruments, Vienna, Austria).
 
FCM Analysis of Anti-Gal, Anti–rabbit RBC, and Anti–pig PBMC
Antibodies.
 
Indirect immunofluorescence staining of WT mouse
cells after incubation with Gal
 
2
 
/
 
2
 
 mouse serum provides an accu-
rate method for detecting the presence of anti-Gal–specific NAb.
However, the presence of surface Ig
 
1
 
 B cells in immunocompe-
tent WT mice complicates the detection of mouse IgM NAb in
sera. Therefore, we elected to use immunodeficient (
 
scid
 
 or
RAG-1
 
2
 
/
 
2
 
) mouse spleen cells and BMC, which lack surface Ig
 
1
 
cells, as a source of WT cells for staining with murine sera. Rab-
bit RBCs (Sigma Chemical Co.) and pig PBMCs were used to
detect serum levels of anti–rabbit and anti–pig antibodies, respec-
tively. 10
 
6
 
 cells were stained for 30 min at 4
 
8
 
C with 10 
 
m
 
l of serially
diluted mouse serum, washed, then incubated with FITC-conju-
gated rat anti–mouse IgM for 30 min at 4
 
8
 
C. The Gal specificity
of GalT KO mouse anti-
 
scid
 
 (or anti–RAG-1
 
2
 
/
 
2
 
) antibodies was
verified by a Gal NAb–specific ELISA assay, and levels of anti–
 
scid
 
/RAG-1
 
2
 
/
 
2
 
 antibodies detected by immunofluorescence cor-
related with titers of anti-Gal Ig observed in the ELISA assay
(
 
r
 
 
 
.
 
0.9).
 
Enzyme-linked Immunospot Assay for Detecting Anti-Gal Anti-
body–producing Cells.
 
Enzyme-linked immunospot (ELISPOT)
assays were performed as described (Xu, Y. and A.D. Thall,
manuscript in preparation). In brief, cell suspensions were serially
diluted (four fivefold dilutions, beginning with 8 
 
3
 
 10
 
5
 
 cells/
well) and placed in triplicate wells in MultiScreen-HA plates
(Millipore Corp., Bedford, MA) precoated with 
 
a
 
Gal-BSA at
4
 
8
 
C overnight. Plates were incubated at 37
 
8
 
C overnight, and
bound antibodies were detected using horseradish peroxidase–
conjugated goat anti–mouse IgM plus IgG (Southern Biotechnol-
ogy Associates Inc., Birmingham, AL). The spot number in each
well was counted by an observer unaware of the treatments admin-
istered to each sample donor.
 
Statistical Analysis.
 
Student’s 
 
t
 
 test for comparison of means
was used for statistical analysis. A 
 
P
 
 value 
 
,
 
0.05 was considered
to be significant.
 
Results
 
Establishment of Mixed Chimerism by Cotransplantation of
GalT KO and Gal
 
1
 
/
 
1
 
 WT BMC to Lethally Irradiated GalT
KO Mice.
 
To determine whether anti-Gal NAb–produc-
ing B cells in GalT KO mice would be rendered tolerant in
the presence of WT hematopoietic cells, experiments were
conducted in which GalT KO mice were lethally irradiated
(9.75 Gy) and reconstituted with 26 
 
3
 
 10
 
6
 
 TCD WT BMC 
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alone, or with 6.5 
 
3
 
 10
 
6
 
 TCD GalT KO plus 26 
 
3
 
 10
 
6
 
TCD WT BMC. GalT KO mice injected with 6.5 
 
3
 
 10
 
6
 
TCD GalT KO BMC, WT mice injected with 26 3 106 TCD
WT BMC, and uninjected GalT KO and WT mice served
as control groups. Mixed chimerism was detected in GalT
KO recipients of a mixture of WT and KO BMC at all
time points studied. The proportion of WT donor cells in-
creased in these mice between 2 and 8 wk after bone mar-
row transplantation (BMT), and was subsequently main-
tained at a steady state. As is shown for a representative
chimera in Fig. 1 A and summarized in Fig. 1 B, mixed
chimerism was observed among both B and T cells in the
PBLs of these animals. Mixed chimerism, including B and
T as well as myeloid lineages, was also detected in the bone
marrow, spleen, and peritoneal cavity at the time of killing
19 wk after BMT (Fig. 1 C, and data not shown). As ex-
pected, at each time point, T and B cells in PBLs of synge-
neic BMT recipients of KO marrow alone (KO®KO) or
WT marrow alone (WT®WT) were fully of KO and WT
origin, respectively. B cells in GalT KO recipients of WT
BMC alone (WT®KO) were almost fully WT in origin
(Fig. 1).
Serum Levels of Anti-Gal NAb in Nonreconstituted, Lethally
Irradiated aGalT KO Mice. To determine whether or not
anti-Gal NAb persisted in the serum after lethal irradiation,
GalT KO mice were lethally irradiated, and their serum
Figure 1. Stable mixed chimerism in GalT KO recipients of mixed WT and KO BMC. PBLs were stained with anti–WT H-2Kb mAb 5F1-FITC and
anti–CD19-PE or anti–CD4-PE plus anti–CD8-PE. Both WT (H-2bxd) and KO (H-2d) cells were detected in GalT KO recipients of mixed WT and
KO BMC. (A) Representative FACSÒ profiles of PBLs from mixed and fully allogeneic chimeras at 12 wk after BMT. The two T cell populations of
lower and higher intensity represent CD41 and CD81 T cells, respectively. (B) Percentages of WT B and T cells in the PBLs of untreated GalT KO mice
(d, n 5 3), WT mice (r, n 5 2), GalT KO mouse recipients of KO BMC (s, n 5 3), WT BMC (h, n 5 5), or mixed KO plus WT BMC (n, n 5
5), and WT mouse recipients of WT BMC (e, n 5 3). Average (6 SD) net percentages (after subtraction of background staining) of WT B cells (per-
centage 5F11CD191 cells/total B cells) and T cells (percentage 5F11CD4/81 cells/total T cells) are shown at the indicated time points. (C) BMC were
prepared from GalT KO recipients of KO BMC (KO®KO), WT BMC (WT®KO), or WT plus KO BMC (WT1KO®KO), or WT recipients of
WT BMC (WT®WT) 19 wk after BMT, and were stained by FITC-conjugated anti–WT H-2Kb mAb 5F1, anti–CD19-PE, and anti–CD4-Bio plus
anti–CD8-Bio, followed by incubation with Cy-chrome-streptavidin. Typical histogram representation of WT (5F11) cells on gated B cells (CD191,
top), T cells (CD41/CD81, middle), and nonlymphoid cells (CD192CD42CD82, bottom [most of these were Mac-11]) are shown. Similar results were
observed for spleen and intraperitoneal cells (data not shown).1338 B Cell Tolerance in Mixed Chimeras
levels of anti-Gal NAb were measured at various times. As
is shown in Fig. 2, no decline in the serum levels of anti-
Gal NAb was observed in irradiated GalT KO mice, even
in animals not receiving BMT, by 14 d after irradiation.
Since all lethally irradiated mice not receiving BMT ap-
peared sick and began to succumb by 10 d after irradiation,
no data were obtained beyond 2 wk after irradiation. The
absence of a significant difference in the levels of anti-Gal
NAb between lethally irradiated GalT KO mice that did or
did not receive reconstituting KO BMC (Fig. 2) suggests
that newly developed B cells derived from BMT inocula
were not a major source of NAb at early time points up to
14 d after irradiation. The relatively constant levels of anti-
Gal NAb in sera of these mice suggest either that the anti-
Gal NAbs are long-lived Igs, or that the irradiation dose of
9.75 Gy does not eradicate all host anti-Gal NAb–produc-
ing B cells.
Disappearance of Anti-Gal NAb in Sera of Mixed Chime-
ras. Levels of anti-Gal NAb were determined by Gal-spe-
cific ELISA assay and FCM analysis. Similar results were
obtained with both assays. As is shown in Fig. 3, sera of
GalT KO mice receiving KO BMC contained levels of
anti-Gal NAb that were similar to those of untreated KO
mice at all time points studied. In contrast, levels of anti-
Gal NAb in sera of WT1KO®KO recipients were re-
duced significantly by 2 wk, and declined further to be-
come undetectable by 4 wk after BMT (Fig. 3 B). A similar
reduction in serum levels of anti-Gal NAb was also ob-
served in lethally irradiated WT®KO recipients. As ex-
pected, sera of WT®WT recipients and of normal WT
control mice did not contain anti-Gal NAb (Fig. 3). Similar
results were observed in two repeat experiments in which
anti-Gal NAb became undetectable in sera of 12 of 12 le-
Figure 2. Serum levels of anti-Gal NAb in lethally irradiated GalT KO
mice. Peripheral blood samples (40 ml) were collected from lethally irradi-
ated (9.75 Gy) GalT KO mice that did (e) or did not (d) receive TCD
GalT KO BMC (5 3 106 cells/mouse), and from 9.75 Gy–irradiated WT
mice (h) at the indicated times, and serum levels of anti-Gal NAb were
measured by FCM. WT scid mouse cells were stained with 10 ml serum,
and NAbs were detected using rat anti–mouse IgM-FITC as secondary
mAb. The anti-Gal NAb (NAB) levels are presented as median fluores-
cence intensity (MFI). Each line represents an individual animal.
Figure 3. Reduced anti-Gal NAb levels in sera of mixed WT1KO®KO chimeras. (A) Representative histograms obtained by FCM analysis show an ab-
sence of anti-Gal NAb in mixed and fully WT®KO chimeras. WT RAG-12/2 mouse cells were stained with sera from normal KO and WT mice and
BMT recipients, and NAbs were detected using rat anti–mouse IgM-FITC as secondary mAb. Typical histogram appearances for normal KO and WT
mice, and for BMT recipients at 4 wk after BMT are shown. (B) Kinetics of serum anti-Gal NAb levels measured by Gal-specific ELISA assay. Sera were
collected from normal KO and WT control mice and BMT recipients at 2, 4, 8, and 12 wk after BMT, and anti-Gal NAb (IgM plus IgG) levels were de-
termined. Average and SDs for the individual groups are shown. Number of animals in each group: normal KO (x), 3; normal WT (j), 2; KO®KO
(d), 3; WT®WT (h), 3; WT®KO (m), 5; WT1KO®KO (r), 5.1339 Yang et al.
thally irradiated GalT KO recipients of mixed WT and KO
BMC, all of which showed mixed chimerism, with pro-
portions of PBL B cells that were WT ranging from 1 to
50% (data not shown).
Tolerance of Anti-Gal–producing B Cells in Mixed Chime-
ras. The reduced NAb levels detected in mixed chimeras
could be due to downregulation of anti-Gal NAb produc-
tion by GalT KO B cells in the presence of WT hemato-
poietic cells, or might reflect adsorption of NAb onto WT
hematopoietic cells. FCM analyses did not provide any ev-
idence for absorption of NAb on WT hematopoietic cells
in chimeras (data not shown). Furthermore, we looked di-
rectly for the presence of anti-Gal NAb–producing B cells
in these animals using an ELISPOT assay. To increase the
sensitivity of the assay and to determine whether or not B
cells of mixed chimeras were tolerant to the Gal epitope on
xenogeneic cells, animals were immunized by intraperito-
neal injection of 109 rabbit RBCs, which express large
amounts of Gal, 19 wk after BMT. Spleen cells, BMC, and
peritoneal cavity cells were analyzed 8 d later for the capac-
ity to produce anti-Gal antibodies as measured by ELISPOT
assay. B cells producing anti-Gal antibodies (both IgM and
IgG) were undetectable in all three tissues of mixed chime-
ras, whereas large numbers of these cells were detected in
normal GalT KO mice and GalT KO recipients of KO
BMC. Results in mixed chimeras resembled those from
WT®KO recipients and, most importantly, those from
normal WT mice (Fig. 4) in which anti-Gal–forming B
cells were not detected. These results show definitively that
mixed WT1KO®KO chimeras are fully tolerant of the
Gal epitope at the B cell level, and rule out the possibility
that the reduced anti-Gal NAb levels in sera of mixed or
fully WT®KO chimeras were caused by adsorption of the
NAb on WT cells.
Specificity of Tolerance of Anti-Gal NAb–producing B Cells in
Mixed Chimeras. To determine whether or not mixed
chimeras were capable of producing antibodies against anti-
gens other than Gal, sera from rabbit RBC–immunized
mixed chimeras were tested for the development of anti–rab-
bit antibodies. As is shown in Fig. 5 A, sera of KO®KO
recipients but not of WT mice or chimeras contained both
anti-Gal and anti–rabbit RBC antibodies after immunization.
However, rabbit RBC–immunized WT mice, WT®KO
chimeras, and WT1KO®KO chimeras showed an increase
in the level of anti–rabbit RBC serum antibodies, but not
with anti-Gal specificity (Fig. 5 A).
Since expression of Gal on porcine cells is a major barrier
to xenotransplantation from pigs to humans, we evaluated
the ability of mixed chimeras to remain tolerant to Gal after
immunization with pig cells. Normal GalT KO mice,
mixed KO1WT®KO chimeras, and control KO®KO
and WT®KO BMT recipients were immunized three
times with 106 pig PBMCs at 15, 16, and 22 wk after
BMT. Serum levels of anti–pig and anti-Gal antibodies
were determined 3 wk after the last injection by FCM and
ELISA, respectively. Again, anti-Gal IgM were detected
only in sera of normal GalT KO mice and KO®KO recip-
ients but not in sera of mixed or fully WT chimeras. In
contrast, increased serum levels of anti–pig IgM were ob-
served in all pig PBMC–sensitized mice (Fig. 5, B and C).
An absence of functional anti-Gal–forming B cells in these
mixed chimeras after immunization with pig PBMCs was
further demonstrated by ELISPOT assays (data not shown).
These results confirm that B cells recovering in mixed
WT1KO®KO chimeras are functional and specifically
tolerant to the Gal epitope.
Figure 4. Reduced number of B cells producing anti-Gal antibodies
(IgM plus IgG) in mixed chimeras. Spleen cells, BMC, and intraperitoneal
cells prepared from BMT recipients or normal (N.) KO or WT mice 8 d
after sensitization with rabbit RBC were serially diluted and used in
ELISPOT assays. (A) Typical ELISPOT wells of spleen cells from indi-
cated mice. (B) Average number of spots (6 SD) (anti-Gal Ig–producing
B cells) in spleen (top), BMC (middle), and intraperitoneal cells (bottom) of
the mice killed 8 d after rabbit RBC immunization.1340 B Cell Tolerance in Mixed Chimeras
Discussion
While the broad species distribution of the a-galactosyl
carbohydrate residue (Gal) has previously limited the analy-
sis of anti-Gal NAb to primate species, the recent develop-
ment of GalT KO mice, which do not express Gal, now
permits evaluation of anti-Gal NAb in a small animal model
system. We have used GalT KO mice to explore the possi-
bility that mixed chimerism could induce specific tolerance
of anti-Gal–producing B cells. We have demonstrated re-
cently that xenoreactive anti–pig NAb can be rapidly re-
stored in C.B-17 scid mice by transfer of immunocompe-
tent adult mouse BMC, indicating that marrow-derived B
cells are efficient producers of IgM NAb (28a). Therefore,
in this study, we reconstituted lethally irradiated GalT KO
mice with GalT KO mouse BMC to restore the potential
to produce anti-Gal NAb, and to evaluate the potential of
cotransplanted WT marrow to tolerize anti-Gal–producing
B cells.
The results of our studies demonstrate that successful in-
duction of mixed bone marrow chimerism leads to toler-
ance of anti-Gal NAb–producing B cells. This conclusion
was supported by the results of ELISPOT assays, which
demonstrated definitively the absence of functional anti-
Gal–producing B cells in mixed chimeras. Furthermore, B
cells in these animals are capable of producing Ig with spec-
ificities other than anti-Gal, indicating that specific toler-
ance of anti-Gal–producing B cells was achieved by the in-
duction of mixed chimerism.
Our ELISPOT data are consistent with the possibility
that tolerance of anti-Gal–producing B cells was induced
by either clonal deletion or anergy, or by both mecha-
nisms. Experiments using transgenic mice have shown that
immature self-reactive B cells can be eliminated by apopto-
sis (clonal deletion) and/or alteration of receptor antigenic
specificity (receptor editing) via signals induced through
Figure 5. Absence of anti-Gal antibodies in sera of xenogeneic cell–sensitized mixed chimeras, and evidence of sensitization to xenoantigens. (A) Se-
rum levels of anti–rabbit and anti-Gal antibodies in rabbit RBC–sensitized mice. Anti–rabbit RBCs and anti-Gal antibodies were detected by staining
rabbit RBC and WT scid mouse cells, respectively, with serially diluted serum, followed by incubation with FITC-conjugated anti–mouse IgM. Left col-
umn, Rabbit RBCs stained with sera of indicated mice collected before (Pre) (10 ml of undiluted serum) and 8 d after (Post) sensitization (10 ml of twofold
diluted serum). Right column, WT scid cells stained with sera collected 8 d after sensitization with rabbit RBC (10 ml of 50-fold diluted serum). Sera from
scid mice (N. SCID) were used as negative controls. (B and C) Serum levels of anti–pig and anti-Gal antibodies in pig PBMC–sensitized mice. Lethally ir-
radiated BMT recipients of KO®KO, WT®KO, or WT1KO®KO and normal GalT KO mice were immunized three times by intraperitoneal injection
of 106 pig PBMCs at 15, 16, and 22 wk after BMT, and sera were collected 3 wk after the last injection. Sera from unimmunized normal WT (N. WT)
and GalT KO (N. KO) mice were used as controls. (B) Serum levels of anti–pig PBMC IgM measured by FCM analysis. Pig PBMCs were stained with
sera (10 ml of undiluted serum) collected from indicated groups (four mice for each group), and anti–pig IgM was detected using FITC-conjugated anti–
mouse IgM. The anti–pig PBMC IgM levels are presented as median fluorescence intensity (MFI). (C) Serum levels of anti-Gal antibodies in pig PBMC-
sensitized normal GalT KO mice (n 5 4; r, dotted line) and BMT recipients of KO®KO (n 5 5; d, solid line), WT®KO (n 5 6; j, dotted line), or
WT1KO®KO (n 5 8; m, solid line) detected by ELISA assay. Average and SDs for the individual groups are shown.1341 Yang et al.
surface Ig cross-linking (29–34). Since the Gal epitope is
recognized as a self antigen in mixed GalT WT1KO®KO
chimeras, the above mechanisms of tolerance induction of
self-reactive B cells would explain the observed tolerance
among NAb-producing B cells resulting from induction of
mixed chimerism. These studies of the important Gal spec-
ificity provide the first demonstration that BMT can induce
B cell tolerance among a polyclonal population of nontrans-
genic NAb-producing B cells with a known specificity.
Although the above mechanisms of B cell tolerance ap-
pear to depend on a signal induction cascade applicable to
immature but not mature B cells, cell surface–associated
antigens are also capable of inducing tolerance among pe-
ripheral mature B cells (29–32, 35–37). Experiments using
transgenic mice have shown that cross-linking of cell sur-
face IgM is able to induce mature B cell tolerance via apop-
totic cell death (deletion) (30, 37). In the present study,
because BMT recipients were lethally irradiated before
BMT and only a limited number of mature Gal2/2 B cells
was included in the BMT inoculum, the majority of GalT
KO B cells in tolerized mixed chimeras developed in the
presence of WT hematopoietic cells. However, the persis-
tence of anti-Gal IgM NAb in nonreconstituted, irradiated
GalT KO mice (Fig. 2) suggests that anti-Gal NAb–pro-
ducing B cells might be radioresistant. Since IgM has an av-
erage half-life of only 2 d in the serum of adult mice (38),
the constant level of anti-Gal NAb in these mice over a 2-wk
period likely reflects the ongoing production of these NAb
by radioresistant B cells. The reduction in anti-Gal NAb
levels observed as early as 2 wk after BMT in recipients of
WT BMC is consistent with the possibility that preexisting
anti-Gal NAb–forming B cells were also tolerized in these
mice. To address the possibility that mixed chimerism can
lead to tolerance of preexisting mature B cells, mixed Gal
chimerism is now being induced in mice conditioned with
a nonmyeloablative conditioning regimen.
These studies demonstrate that mixed chimerism has the
potential to induce specific tolerance of anti-Gal NAb–
producing B cells, in addition to the T cell tolerance to xe-
noantigens demonstrated previously (21, 39). To our knowl-
edge, mixed chimerism is the first approach shown to achieve
efficient and permanent inhibition of polyclonal antidonor
NAb production. These findings suggest that this approach
may ultimately contribute to the successful use of discor-
dant xenogeneic organs in clinical transplantation. The po-
tential of this strategy to induce both B and T cell tolerance,
and thus to permit solid organ xenograft acceptance in a
pig-to-primate species combination, is currently under in-
vestigation.
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